Monthly Archives: August 2020

eMagin to Present at The LD 500 Virtual Conference

LOS ANGELES, CA / ACCESSWIRE / August 27, 2020 / eMagin Corporation (NYSE American:EMAN), a leader in the development, design and manufacture of Active Matrix OLED microdisplays used in Military and Commercial AR/VR devices, and other near-eye imaging products, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 1:40 PM PST / 4:40 PM EST. CEO Andrew G. Sculley will be presenting to a live virtual audience.

Register here: https://ld500.ldmicro.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View eMagin's profile here: http://www.ldmicro.com/profile/EMAN

Profiles powered by LD Micro – News Compliments of Accesswire

About eMagin

The leader in OLED microdisplay technology for the next generation of computing and imaging devices, serving world-class customers in the military, consumer, medical and industrial markets. We invent, engineer and manufacture display technologies of the future in the USA, including our Direct Patterning Technology (dPd) that will transform the way the world consumes information. Since 2001, our microdisplays have been, and continue to be, used in AR/VR, aircraft helmets, heads-up display systems, thermal scopes, night vision goggles, future weapon systems and a variety of other applications. www.emagin.com

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

eMagin Corporation
Mark A. Koch, Acting Chief Financial Officer
845-838-7951
mkoch@emagin.com

Affinity Growth Advisors
Betsy Brod
212-661-2231
betsy.brod@affinitygrowth.com

SOURCE: eMagin Corporation

ReleaseID: 603513

Ovation Science Ships DermSafe Hand Sanitizer to China

Collaboration Phase Entered for DermSafe

VANCOUVER, BC / ACCESSWIRE / August 27, 2020 / (CSE:OVAT) Ovation Science Inc. ("Ovation" or the "Company") is pleased to announce that it has shipped DermSafe hand sanitizer in bulk supply of 200 kilograms to its distributor in Guangzhou, China. This shipment will help facilitate their development of a novel mechanism to dispense DermSafe using an individual use, unique delivery device. This relationship aims to advance the distribution of DermSafe into China, the world's largest country with a population of 1.43 billion people.

This collaboration is the first phase for a potential distribution agreement to import DermSafe hand sanitizer into China once the delivery device has been designed and regulatory approval has been obtained. It also establishes a cooperative effort to conduct tests and exchange exploratory information in order to assess and develop their device which will provide a unique way to deliver DermSafe in packets as a single use. This preliminary shipment of DermSafe has been placed from Ovation's recently announced Canadian production of DermSafe at its contract cGMP manufacturer in Ontario.

"We are excited to see the progress to develop a truly innovative mechanism to deliver and market DermSafe," said Terry Howlett, President of Ovation. "This collaboration demonstrates our strong commitment to help fight this pandemic globally and to make a difference in people's safety." He further commented, "Previously we had shipped DermSafe to China under their "green channel" which temporarily facilitated the foreign exchange of goods related to the fight against this pandemic; however this has since closed. Should this collaboration progress into a distribution agreement, it is the Company's intent to supply DermSafe manufactured in Canada in bulk to China.

The active ingredient in DermSafe, chlorhexidine gluconate, has been used in hospitals worldwide for over fifty years as a pre-surgical hand scrub due to its ability to kill both gram-negative and gram-positive bacteria and viruses. Furthermore, the Company also recently announced on July 8th, 2020 that DermSafe was successfully tested against human coronavirus (Surrogate to SARS-CoV-2; the virus that causes COVID-19), showing a 99.97% reduction in the virus at two time points. DermSafe does not contain alcohol and therefore is non-drying and does not have some of the issues that alcohol-based products do. Visit www.dermsafe.com for more information and to order.

Statements have not been evaluated by Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.

For information about DermSafe and to purchase visit: https://dermsafe.com

For information about Ovation Science products visit: https://ovationscience.com/products/.

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance of the development of a new delivery devise, approval or future sales in China. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact:

INVESTOR RELATIONS:

Sebastian Kunyz: ovat@kincommunications.com Phone: 604-684-6730 or Toll Free at 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran: doreen@ovationscience.com Phone: 604-283-0903 ext. 4

SOURCE: Ovation Science Inc. 

ReleaseID: 603553

Gratomic Announces Health and Safety COVID-19 Protocol Implementation at Its Aukam Graphite Mine Site

TORONTO, ON / ACCESSWIRE / August 27, 2020 / Gratomic Inc. ("GRAT" or the "Company") (TSXV:GRAT)(FRA:CB81)(WKN:A143MR) wishes to announce that all necessary precautions and protocols have been implemented to maintain worker health and safety during this unprecedented time now that its workers have returned to the Aukam mine site.

Workers have been provided with all necessary personal protective equipment (PPE) and have been provided safe accommodation and transportation to and from the mine site. Training has been provided to all staff and social distancing is implemented for the protection of all individuals on site. The Company's Health and Safety Officer has received his COVID-19 safety certification to ensure all measures are followed correctly.

Interregional COVID-19 travel restrictions prevent travel between Namibian regions. However, the mine crew is unaffected by these restrictions because all mine-related travel required by the crews falls within the Karas region. All necessary precautions have been implemented to maintain the health and safety of the crew amid the pandemic.

Upon return to the site, the crew began excavation work as well as construction of multiple foundational platforms required to accommodate the new equipment. The concrete foundations will house the equipment and various additional key processing components.

In addition to concrete foundational platforms, the team will install various electrical systems, water pumps, and plumbing equipment. These additions will link the circuits and complete the construction of the facility.

About Gratomic Inc.

Gratomic is a materials company focused on mine to market commercialization of graphite products and components for a range of mass market products. The Company currently holds two off-take purchase agreements for graphite product sourced from the Aukam facility. One agreement is with TODAQ and the other is with Phu Sumika. The Company is listed on the TSX Venture Exchange under the symbol GRAT.

For more information: visit the website at www.gratomic.ca or contact:

Arno Brand at abrand@gratomic.ca or 416 561-4095

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

FORWARD LOOKING STATEMENTS:

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: Gratomic Inc.

ReleaseID: 603562

Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)

EDISON, NJ / ACCESSWIRE / August 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) "Hepion", a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it will present a poster on CRV431's antifibrotic activity at the Digital International Liver Congress™ 2020 (EASL), taking place from August 27-29, 2020.

Dr. Joseph Kuo will present a preclinical study evaluating CRV431's ability to reduce hepatic fibrosis and fatty diet-induced body weight gain in a mouse model of NASH.

Presentation Details
CRV431 decreases diet- and chemical-driven fibrosis in livers of mice
Poster presentation number: FRI-239
Authors: Joseph Kuo1, Erika Cabrera1, Patrick Mayo2, Daren Ure2, Robert Foster2, and Philippe Gallay1
1Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, USA. 2Hepion Pharmaceuticals, Edison, New Jersey, USA.
Date: Friday, August 28, 2020

About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on Hepion Pharmaceuticals' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals' Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:
Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

SOURCE: Hepion Pharmaceuticals, Inc.

ReleaseID: 603559

Resgreen Group Designs New Disinfecting Autonomous Mobile Robot to Meet Increasing Demand

CLINTON TOWNSHIP, MI / ACCESSWIRE / August 27, 2020 / Resgreen Group (OTC PINK:RGGI) Resgreen Group (RGGI), a leading mobile robot company, today unveiled designs of Wanda, an industry-changing, light-duty Autonomous Mobile Robot (AMR) that uses UVC lightsto disinfect everything from plants and warehouses to hotels, office buildings and airplanes. Wanda will be equipped with dual 50-Watt UVC lights in the 254 – 270 nm range that kill 99 percent of harmful pathogens. The vehicle will be ready for validation testing as early as next week.

"Due to the current situation, we have been overwhelmed with requests for an unmanned vehicle that can sanitize facilities from government officials, building owners and hotel managers," said Parsh Patel, CEO of RGGI. "These individuals simply can't hire enough workers to consistently, thoroughly and reliably disinfect spaces with 99 percent accuracy."

Wanda will be the smallest vehicle in RGGI's product line-up, which also includes Pull Buddy, a low-profile AMR. In addition to the sweeping UVC lights, Wanda will be able to carry more than 300 pounds of packages and mail. The vehicle's base will be 3D printed in a biodegradable sugar-based plastic. Itwill feature a lithium-ion battery for quick, opportunity charging to enable 24/7 operation without human intervention.

"We shifted focus to completing production of Wanda before Pull Buddy because of increasing demand and supply chain issues. Due to the coronavirus pandemic, we are having difficulty sourcing parts for Pull Buddy from overseas companies. Furthermore, the crisis is driving increased pressure to deliver a disinfecting autonomous vehicle to ourcustomers, as soon as possible." said Parsh Patel, CEO of RGGI. "With its less complex design, Wanda uses only parts that are manufactured in the U.S., while also filling an enormous and immediate need."

RGGI's engineers are experienced in designing and manufacturing a wide variety of AMRs, Automatic Guided Vehicles and Artificial Intelligent Robots – making it easy to quickly change course to rapidly design and develop Wanda.

The UVC lights on Wanda break down the DNA or RNA of dangerous viruses and bacteria found in drinking water, wastewater, surfaces and even air. To be most effective, the light needs to be able to reach all surfaces and equipment, including corners and underneath furniture. The autonomous vehicle will include human detection sensors to protect against unwanted exposure to UVC light.

About Resgreen Group International, Inc. (RGGI)

RGGI is a leading developer of Artificial Intelligence Robotics (AIRs), Autonomous Mobile Robots (AMRs), and Automatic Guided Vehicles (AGVs). RGGI's highly skilled engineers have years of experience in the material handling and robotics industries, which has led to significant intellectual property for the company.

RGGI also provides consulting services including backend operational oversight, material handling assessment, work-flow analysis, and steady state yield management using artificial intelligence, technology and management systems. For more information visit http://resgreenint.com.

Rendering of Wanda Autonomous Mobile Robot (AMR) sanitizing an office cafeteria.

Rendering shows Wanda, disinfecting Autonomous Mobile Robot (AMR) cleaning a hotel room.

Contact:​Sarah Carlson
​​scarlson@companystorytellers.com
248.755.7680 cell

SOURCE: Resgreen Group International Inc

ReleaseID: 603566

Else Nutrition Commences First phase of Full-Scale Marketing Campaign for Launch of New Toddler Nutrition Product

VANCOUVER, BC / ACCESSWIRE / August 27, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) ("Else" or the "Company"), a developer of plant-based alternatives to dairy-based baby nutrition, is pleased to announce the launch of it's first phase of the marketing campaign behind the North American Launch of its Plant-based Complete Nutrition product for Toddlers.

Else has engaged with nearly 50 key influencers (covering social channels: Instagram, Facebook, and blogs), with a combined social media following of over 3.5 million followers / fans. The influencers have been handpicked for their enthusiastic following in the mommy/parenting, vegan, healthy-eating, and baby food communities. The influencers will engage with their respective audience by posting branded partner content videos and photography of their children using Else Toddler Nutrition throughout the duration of the influencer campaign. Additionally, the Company has recently signed Ms. Hilaria Baldwin (@hilariabladwin) to a 6-month branded content partnership, which includes high profile media appearances.

Furthermore, Else has partnered with 2 significant online communities, to further amplify awareness and reach to encourage trial size orders of its new, Plant-based Complete Nutrition for Toddlers. The Company has partnered with mindbodygreen (MBG), the leading U.S. health and wellness community, which has an aggregate audience of over 27 million people. Else will be featured on paid podcast spots, as well as on MBG's website and newsletter, as a branded partner throughout September. Else Nutrition is also ramping up sampling efforts of the Toddler Nutrition product to over 6,000 moms in key cities across the U.S., via a partnership with the Moms Meet network of mothers.

In addition to the influencers and online community engagement Else has signed Dr. Jennifer Trachtenberg M.D. "Dr. Jen" as she is known to her patients, is a Board Certified Pediatrician, nationally-renowned parenting expert, author, and mother of 3. She is also Assistant Clinical Professor of Pediatrics at Thelcahn School of Medicine at Mount Sinai, and is hailed as "Dr. Mom" by Dr. Mehmet Oz. Dr. Trachtenberg will create branded partner content for Else for distribution on digital platforms, and will provide professional consultation services spanning consumer and medical marketing. She is a regular contributor on child development and nutrition issues to Parents Magazine, the New York Times, and Today.com.

"I'm excited to be partnering with Else Nutrition. It's a revolutionary change in toddler formula, or as I like to call it – non-dairy milk alternative for kids – that's a smart, healthy choice and that tastes good too! The word needs to be spread to moms, dads, pediatricians, nutritionists about this new option for kids' growth and development," said Dr. Trachtenberg.

Else Nutrition's Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available for sale on Else's e-store at elsenutrition.com, and will soon be available on Amazon.com. Consumers can order single 22 oz cans and 4-packs.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For more information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: hamutaly@elsenutrition.com
P: +972(0)3-6445095

Mr. Sokhie Puar, Director of Else Nutrition
Email: sokhiep@elsenutrition.com
Telephone: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings 

ReleaseID: 603563

Memex Inc. Reports Q3-2020 Results

BURLINGTON, ON / ACCESSWIRE / August 27, 2020 / Memex Inc. ("Memex" or the "Company") (TSX-V:OEE), a leader in Industrial Internet of Things (IIoT) manufacturing productivity software, today released financial and operational highlights for its third quarter 2020 ending June 30, 2020. All results are reported in Canadian dollars. A complete set of June 30, 2020 Consolidated Financial Statements and Management's Discussion & Analysis has been filed at www.sedar.com.

Summary financial highlights for the three-months ended June 30, 2020:

Memex reported revenue of $554 thousand for the three-month period, compared to $916 thousand in the same period a year ago (a 40% decrease);
Bookingsi for the period totalled $471 thousand versus $1.09 million in the year ago period, a 57% decrease;
Finished the period with $1.11 million in project backlogii, $82 thousand less than at September 30, 2019;
Gross margin was 87.3% for the period compared to 74.3% for the year-ago period;
Cash generated from operations (before changes in non-cash items) of $34 thousand was a $218 thousand improvement from the $184 thousand consumed from operations in the same period a year ago;
Net and comprehensive income for the period of $49 thousand ($0.000 per share) is a $303 thousand improvement from the to $254 thousand ($0.002 per share) net and comprehensive loss for the same period a year ago;
$352 thousand working capital deficit and $565 thousand in cash on hand at June 30, 2020, compared to $356 thousand in working capital surplus and $740 thousand in cash at September 30, 2019;
The Company was able to take advantage of Government of Canada's Canada Emergency Wage Subsidy ("CEWS") and Regional Relief and Recovery Fund Loan ("RRRF") initiatives to stabilize its financial position in the wake of the COVID-19 Pandemic; and
In June, FedDev finalized changes to the Company's IBI term loan repayment schedule which included the repayment term being extended by 14 months to November 2024, payment reductions of $84 thousand in the current fiscal year and $114 thousand in fiscal 2021; the restructuring required a $57 thousand present value discount adjustment (reduction of interest expense) during the quarter.

Summary financial highlights for the six-months ended June 30, 2020:

$1.75 million in revenue for the nine-month period versus $2.32 million in the year ago period (a 24% decrease);
Bookingsi totalled $1.88 million versus $2.98. million in the same period a year ago, a 37% decrease;
Gross margin was 73.1% for the period compared to 71.4% for the year-ago period;
Cash consumed from operations in the first three quarters of 2020 (before changes in non-cash items) was $601 thousand, $150 thousand less than the same period a year ago; and
Net and comprehensive loss for the period was $749 thousand ($0.006 per share), compared to $934 thousand ($0.007 per share) for the same period a year ago.

Management commentary:

"In the wake of the COVID-19 pandemic, we remain satisfied with our financial results," said Memex CEO David McPhail. "The combination of the closure of the U.S./ Canada border and a great deal of U.S. manufacturing grinding to a halt due to COVID-19 have continued to negatively affect our ability to both generate and recognize revenue. We believe this lag in customer willingness and/or ability to make purchase commitments will continue into Q4. However, interest in MERLIN remains constant and sales conversations continue, even with prospects that have temporarily closed their facilities. We have been able to reduce our costs to react to the current situation, and hope to resume more normal activities once the border opens."

Selected financial information:

For the

 

Three-months periods ended
June 30

 
 

Nine-months periods ended
June 30

 

(Canadian dollars – in thousands except per share and margin%)

 
2020
 
 
2019
 
 
Change
 
 
2020
 
 
2019
 
 
Change
 

Revenue

 
 
554
 
 
 
916
 
 
 
– 40
%
 
 
1,752
 
 
 
2,319
 
 
 
– 24
%

Bookingsi

 
 
471
 
 
 
1,094
 
 
 
– 57
%
 
 
1,879
 
 
 
2,981
 
 
 
– 37
%

Gross margin %

 
 
87.3
 
 
 
74.3
 
 
 
+ 17
%
 
 
73.1
 
 
 
71.4
 
 
 
+ 2
%

Operating expenses

 
 
432
 
 
 
889
 
 
 
– 51
%
 
 
1,905
 
 
 
2,520
 
 
 
– 24
%

Cash generated (utilized) in ops activities1

 
 
34
 
 
 
(184
)
 
 
+ 118
%
 
 
(601
)
 
 
(751
)
 
 
+ 20
%

Net and comp income (loss) for the period

 
 
49
 
 
 
(254
)
 
 
+ 119
%
 
 
(749
)
 
 
(934
)
 
 
+ 20
%

Basic and diluted loss per share – period

 
 
0.000
 
 
 
(0.002
)
 
 
+ 106
%
 
 
(0.006
)
 
 
(0.007
)
 
 
+ 20
%

Before changes in non-cash working capital balances

As at

(Canadian dollars – in thousands except WC ratio)

 
June 30,
2020
 
 
September 30, 2019
 

Cash on hand

 
 
565
 
 
 
740
 

Current assets

 
 
1,003
 
 
 
1,901
 

Total assets

 
 
1,890
 
 
 
2,189
 

Current liabilities

 
 
1,355
 
 
 
1,545
 

Working capital surplus (deficit)*

 
 
(352
)
 
 
356
 

Working capital ratio**

 
0.74 to 1
 
 
1.23 to 1
 

Backlogii

 
 
1,107
 
 
 
1,189
 

* Working Capital = current assets – current liabilities
** Working Capital ratio = current assets / current liabilities

About Memex Inc.:

Established in 1992, Memex grew to be an industry leader in Industry Internet of Things (IIoT) through the development of MERLIN Tempus, an award-winning platform that delivers real-time, tangible increases in manufacturing productivity. Memex is on the leading edge of industry trends in computing power, machine connectivity, industry standards, advanced software technology, and manufacturing domain expertise.

Our persistent pursuit of innovative IIoT solutions led to a comprehensive understanding of the challenge's manufacturers face. We made it our mission to, "successfully transform factories of today into factories of the future." As the global leader in Machine to Machine (M2M) connectivity solutions, our hardware and software products create unparalleled visibility at all levels, from "Shop-Floor-to-Top-Floor."

The MERLIN Tempus Suite provides effective quantification and management of Overall Equipment Effectiveness (OEE) by revealing hidden capacity using real-time objective data. Further, it offers sustainable benefits that enable world-class OEE such as reducing costs, incorporating strategies for continuous LEAN improvement, and boosting bottom-line financial performance. For more information, please visit: www.MemexOEE.com

Neither the TSX Venture Exchange nor its Regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

i & ii These non-IFRS financial measures are identified, defined and reconciled to their closest IFRS measures, revenue and unearned revenue, within our Management's Discussion and Analysis for the periods ended June 30, 2020 and 2019, in the section "Other Financial Measures." That MD&A is available at www.sedar.com under our company profile.

For investor inquiries please contact:

Ed Crymble, Chief Financial Officer

905-635-1540

investor.relations@memexOEE.com

 

David McPhail, President & CEO

905-635-1540

investor.relations@memexOEE.com

Sean Peasgood, Investor Relations
647-977-9264
sean@sophiccapital.com

SOURCE: Memex Inc.

ReleaseID: 603484

Update on YDX and Amuka Esports Partnership

VANCOUVER, BC / ACCESSWIRE / August 27, 2020 / YDX Innovation Corp (TSXV:YDX)(OTC PINK:YDRMF)(FSE:A2PB03) ("YDX" or the "Company"), is pleased to provide an update on the July 6th news release regarding a strategic partnership with Amuka Esports ("Amuka").

This partnership will see these two companies working together on three (3) core esports projects.

"Project V" is an initiative where the partnership will co-develop an esports tournament series led and organized by an all-female team. The intention of this tournament will be to support, showcases and empower all aspects of women in gaming. Additionally, we strive to encourage and inspire new female gamers to get involved and participate in the gaming community. Both Companies have support of their current corporate sponsors towards meeting initial goals while generating strong top line revenues.
The Amuka team will support YDX in creating the roadmap and infrastructure for the [previously announced] Comic Convention International Esports League. This will include monetization from tournament registration, merchandise, event sponsorship, licensing streams and VOD media rights.
Amuka has committed to building the base for an upcoming tournament framework to launch a completely innovative form of competitive VR gaming, or ‘VSports'. YDX will lend its titles from the Arkave library and from third-party catalogues to support the competitive side format. YDX will also provide its technology and expertise in Virtual Reality, in addition to resources and key industry contact.

"We are in a great position to create several high-value esports assets that will drive strong revenues through its global reach and appeal. We are excited to be working with Amuka Esports to accelerate these initiatives which will start to materialize as early as Q4 of 2020," according Daniel Japiassu, CEO of YDX Innovation.

Amuka Esports has produced over 300+ events, largely in the Tier 1 and Tier 2 gaming titles but sees a new opportunity in the fusion of VR and traditional esports.

Ben Feferman, CEO of Amuka Esports added, "Our goal is not to be evolutionary, but revolutionary. You need to think what the next generation of alternative competitive gaming looks like and I'm convinced that is going to be VR. We want to pioneer and create the foundation for the future esports leagues and with YDX Innovation and their current content partners, we will have a significant head start."

The first YDX Innovation esports initiative, ‘Project V', is scheduled to take place in Q4 of 2020.

About Amuka Esports
Amuka Esports https://amukaesports.com is Canada's leader in esports venues, leagues and tournaments. Last year they produced 200+ events at their venues in Toronto, Windsor and online. In addition they own and operate a tier 2 CSGO team, an esports incubator and an esports lifestyle and content brand.

About YDX Innovation
YDX Innovation Corp. (TSXV:YDX :: www.ydxinnovation.com) is a global leader in the commercialization of immservive new technologies that incorporate virtual reality, augmented reality, esports and gaming. Its core business seeks to monetize through licensing its IP, developing interactive exhibitions and through esports tournaments and content.

Arkave VR Arena – https://sales.arkavevr.com/ – is a proprietary gaming platform that brings location based virtual reality to any location-based event or entertainment centre. Arkave features state-of-the-art free roam technology coupled with a vast library of both in-house and third-party games.

YDreams Global – www.ydreamsglobal.com – has developed over 2,000 interactive and immersive experiences for some of the largest global brands including Disney, NBA, Adidas, Cisco, Nokia, Nike, Mercedes-Benz, Coca-Cola, Santander, AB InBev, Qualcomm, Unilever, Fiat and the City of Rio de Janeiro.

BEAT Gaming – www.beat.gl – is an industry-leading esports company that has organized internationally recognized events such as the Dota 2, Overwatch and PUBG BEAT Invitational. Since its creation, BEAT has organized over 30 professional and semi-pro esports events, which has reached over 40 million viewers globally.

Purple Mage Advisors – www.purplemage.com – Purple Mage Advisors (PMA) is a research and data analysis firm that specializes in player recruitment and development in the gaming industry. PMA helps esports and gaming companies with industry reports, player recruitment, player training, data analysis and relevant statistical reporting.

More Information:
Daniel Japiassu
Director and CEO
dj@ydx.rocks
(604) 704-6466

contact@ydxinnovation.com | www.ydxinnovation.com | www.youtube.com/ydreamsglobal

This news release may contain "forward-looking statements" within the meaning of applicable Canadian securities laws, including, without limitation: negotiations with sponsors and creation of a major esports brand. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. The Company's statements expressed or implied by these forward-looking statements are subject to a number of risks, uncertainties, and conditions, many of which are outside of the Company's control, and undue reliance should not be placed on such statements. Forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Transaction, including: that the Company's assumptions in making forward-looking statements may prove to be incorrect; adverse market conditions; the inability of YDX to complete the Transaction on the terms announced or at all; the inability of YDX to finance any necessary costs associated with the Transaction; risks relating to the satisfaction of the conditions to closing the Transaction; that future results may vary from historical results; and that market conditions or competition may affect the outcome of the Transaction and the business. Except as required by securities law, the Company does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: YDX Innovation Corp.

ReleaseID: 603554

ESAIYO adds former Bad Boy Ent New Media Manager Kwasi Asare as Co-Founder

ESAIYO, a media technology company, has added Kwasi Asare-a serial entrepreneur-to their team. In addition to his role as CMO and co-founder, Mr. Asare will be joining the Board of Directors.

Champaign, United States – August 27, 2020 /PressCable/

ESAIYO, a media technology company, has added Kwasi Asare-a serial entrepreneur-to their team. In addition to his role as CMO and co-founder, Mr. Asare will be joining the Board of Directors.

Mr. Asare, a University of Pennsylvania graduate, began his career as an investment banker at institutional investment bank, Citigroup/Salomon Smith Barney, before moving into the entertainment industry, where he quickly became the New Media/Social Media Manager for Sean “Diddy” Combs. While working with Combs, Kwasi ran the digital marketing and social media platforms for many of Diddy’s brands-including; Ciroc, Sean John Fragrance, and Bad Boy Entertainment.

Mr. Asare is also an experienced start-up founder and co-founder. He has founded, consulted for and advised numerous companies and agencies. His client list includes; Startup America, Google, Facebook, Bit Torrent, The Consumer Technology Association, Microsoft, Universal Music, Apple, Monster Products etc.

“I have known Kwasi for nearly a decade. His knowledge base, experience, work ethic, and immediate understanding of ESAIYO make him a perfect fit to run marketing and help to drive our business strategy. As expected, he has already begun to make a significant impact.” – said ESAIYO CEO, Raymond St. Martin.

“I have been a fan of Raymond St. Martin and his work on various platforms and nonprofits for nearly a decade. When he approached me with the ESAIYO concept and intellectual property, I immediately saw multiple use cases for the technology and an opportunity to create significant value and impact across the globe. I am honored and inspired to join the team as CMO, Cofounder, and Board of Directors member.”

About ESAIYO: The ESAIYO platform offers users the opportunity to digitally attach memories, authentication, media, provenance, and other defining data to physical and digital objects. ESAIYO is launching their first product, the ESAIYO mobile app, in partnership with the Clemente Museum in Pittsburgh.

Press Contact: Press@esaiyo.com

For more information visit: www.esaiyo.com

Contact Info:
Name: Kwasi Asare
Email: Send Email
Organization: ESAIYO
Address: POB 6084 , Champaign, IL 61826, United States
Website: https://www.esaiyo.com

Source: PressCable

Release ID: 88974505

American Kidney Fund to Hold Congressional Briefing on Stark Health Disparities in COVID-19 Pandemic

Sept. 16 event will address COVID-19 impact on the same communities devastated by kidney disease

ROCKVILLE, MD / ACCESSWIRE / August 27, 2020 / The American Kidney Fund (AKF) will hold a Congressional briefing to focus on factors that have contributed to the disproportionate impact of COVID-19 on communities of color. The briefing-COVID-19, Health Disparities and the Social Determinants of Health-will take place Sept. 16 from 1-2 p.m. ET via Zoom. Bringing together a panel of national experts, the briefing will explore the dramatically higher rates of coronavirus infections, hospitalizations and deaths among people of color and those with end-stage renal disease (ESRD, or kidney failure), and how addressing the social determinants of health is part of the solution to tackle these health disparities.

Speakers will include:

Congresswoman Nanette Diaz Barragán (D-CA-44), member of the House Committee on Energy and Commerce, and Committee on Homeland Security
Former Congresswoman Donna M. Christensen, M.D. (D-VI), past chair, Congressional Black Caucus Health Braintrust, and current member of the AKF Board of Trustees
Sindy Benavides, CEO of the League of United Latin American Citizens (LULAC)
Oliver Brooks, M.D., immediate past president, National Medical Association, and chief medical officer of Watts Healthcare
Eduardo Sanchez, M.D., M.P.H, FAAFP, chief medical officer for prevention for the American Heart Association
LaVarne A. Burton, AKF president and CEO

"Kidney disease and kidney failure have long had a disproportionate impact on racial and ethnic minorities-the same communities now devastated by COVID-19," Burton said. "As Black Lives Matter and other movements to end systemic racism continue to gain momentum, the underlying social determinants of health that have a demonstrable impact on the health, lives and livelihoods of people of color must also be understood and addressed by lawmakers."

According to data from the Centers for Medicare & Medicaid Services (CMS), Black Medicare beneficiaries are being hospitalized for COVID-19 at four times the rate of white beneficiaries, while Native American and Hispanic Americans have the second and third highest rates, respectively. ESRD Medicare beneficiaries, in particular, have been hit harder by COVID-19 than any other group-they have the highest rates of infection among all beneficiaries and have also been hospitalized at eight times the rate of the general Medicare population.

AKF's briefing is open to members of Congress, Congressional staff, other policy makers, media and the general public. Registration is open at KidneyFund.org/SDOH.

The Congressional briefing is part of AKF's Kidney Action Week from Sept. 14-18. Kidney Action Week is a first-of-its-kind event in the COVID-19 era, focusing on kidney health and kidney disease awareness and prevention. Due to the health and safety concerns of the pandemic, AKF has transformed its flagship in-person kidney disease community screening event, Kidney Action Day, to a virtual event to continue reaching at-risk individuals across the country.

About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation's leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

CONTACT:
Alice Andors
Senior Director of Communications
aandors@kidneyfund.org
11921 Rockville Pike, Suite 300, Rockville, MD 20852
Work: 240-292-7053 Mobile: 703-609-6085
KidneyFund.org

Links
https://www.kidneyfund.org/sdoh

SOURCE: American Kidney Fund

ReleaseID: 603701